Login to Your Account



Exithera 'teas' off at AHA with strong phase I data

By Randy Osborne
Staff Writer

Tuesday, November 14, 2017

Exithera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after phase I data showed the I.V. version of the antithrombotic safe and well-tolerated in healthy volunteers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription